Evotec's CFO Steps Up as the Market Waits for Proof
Published on 09/18/2026 at 17:20 | Editorial boerse-global.de
Claire Hinshelwood chose her moment carefully. With Evotec's share price wallowing near multi-year lows, the German drug developer's finance chief took the stage at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday and offered investors something the company has struggled to deliver lately: a reason to look forward.
The operating indicators, she said, are moving "in the right direction" and should eventually feed through to revenue. The "Horizon" cost-cutting program is running to plan, and the pipeline of potential business deals remains robust, Hinshelwood added, according to dpa-AFX.
No fresh guidance, no new contracts — just a deliberate reframing of the story. For a company that has spent months on the back foot, that alone was enough to move the needle.
A One-Day Pop in a Bruising Year
Evotec shares climbed as much as 3.9% on Friday, touching 3.02 euros, up from Thursday's close of 2.90 euros. By another reading of the session, the stock was up 3.4% at 3.00 euros. Either way, the advance offers scant comfort against the broader picture: the equity has shed 45% over the past year and sits roughly 61% below the 7.75-euro peak it reached last November.
The technicals suggest the bounce is more mechanical than meaningful. With a relative strength index of 38.8, the stock had been drifting into oversold territory, and Friday's move looks like a reflex rather than a change of heart. Thirty-day volatility of 38% underscores just how jittery the market has become.
Should investors sell immediately? Or is it worth buying Evotec?
The recent track record does little to inspire confidence. Evotec reaffirmed its downgraded full-year guidance about three weeks ago, and the shares have given up 10.7% since. A research collaboration with Plectonic Biotech, announced roughly a fortnight ago, failed to break the slide — the stock has lost 8.8% since that news landed.
The Science Keeps Moving
What Hinshelwood can point to is a pipeline that refuses to stand still. Just – Evotec Biologics, the group's antibody arm, has pushed JST-018 — an antibody cocktail targeting orthopoxviruses — into a Phase 1 clinical trial. The candidate was developed under the Accelerated Antibodies Program run by the U.S. Department of Defense, a detail that matters for more than scientific reasons: government-backed programs tend to come with a degree of funding certainty that is hard to find in a soft industry climate.
Separately, Evotec struck a research partnership with Plectonic to explore novel T-cell-activating approaches in solid tumors. Both developments fit the same thesis — that Just – Evotec Biologics can convert its antibody platform from a research shop into a source of clinically valuable programs.
Whether that thesis holds is now the single most important question for the stock. If JST-018 progresses safely and effectively through Phase 1, it would signal that Evotec's biologics unit can stand on its own outside traditional pharma partnerships. If the program stalls, or if the Pentagon deal proves a one-off without follow-on work, the optimism evaporates quickly.
The Numbers Still Hurt
The financial backdrop remains the central problem. Revenue for the first half of 2026 fell 19.2% to 300.1 million euros, while adjusted EBITDA swung from minus 1.9 million euros a year earlier to minus 42.7 million euros. Evotec published the final second-quarter and first-half figures in mid-August, confirming its annual forecast at the same time.
That combination — shrinking sales and a widening operating loss — is what keeps investors on edge. The margin-poor contract research business is the root of the guidance cut, and it is precisely the segment that the biologics pipeline would need to offset.
Evotec at a turning point? This analysis reveals what investors need to know now.
Adding to the mix is a capital increase, which brings fresh funding but also dilution — a risk the 45% year-to-date decline already partly reflects. And then there is an unconfirmed report that Triton Partners may be interested in acquiring the company. No timing, no offer price, no substantiation. Such speculation can lift a stock briefly, but it can fade just as fast.
What to Watch Next
For the recovery to hold, the biologics story needs to keep delivering. Absent negative trial data from JST-018, the shares could continue to gravitate toward short-term moving averages — the 50-day line sits at 3.38 euros. Should the narrative crack, whether through disappointing interim results or the quiet death of the takeover chatter, a retest of the recent low becomes the likely path.
The next real test for shareholders will be further disclosures on JST-018 and any additional detail on the capital raise. Until then, Evotec remains a stock for those with a high tolerance for risk — and a conviction that the diversification strategy built around Just – Evotec Biologics deserves more weight than the struggling core business.
Ad
Evotec Stock: New Analysis - 18 September
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
